Large speculators in CME Bitcoin futures held a net long position of 2,418 contracts for the week of October 20, 2026, slightly down from 2,534 the previous week. Meanwhile, speculators reduced their short positions across most US Treasury futures, except for an increase in short positions in UltraBond Treasury futures. The euro remained deeply net short. This data from the Commodity Futures Trading Commission's Commitments of Traders report shows mixed positioning, with some Bitcoin traders hedging rather than betting outright. Investors will watch the upcoming report on October 30 to see if these trends continue.
The story on Bitcoin futures speculators is complemented by Pluang's cryptocurrency market data. For readers following digital assets, 36 out of 50 major cryptocurrencies rose while 13 fell. Notable movers include BCH at Rp5.144.657 with a 4.45% gain and a typical hold time of 69 days, SAND down 4.41%, and COTI up 3.90%. This snapshot is as of Oct 24, 2026 02:31 WIB.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
